01.02.2022 – 20:52
Luxembourg (ots / PRNewswire)
CordenPharma, a leading full-service Contract Development & Manufacturing Organization (CDMO) providing APIs, excipients, pharmaceuticals and related packaging services, today announced the completion of the acquisition of three manufacturing sites from Vifor Pharma, ultimately becoming Corden Pharma Friborg SA ( including its branch in Ettingen) in Switzerland and Corden Pharma Lisbon SA in Portugal.
dr Michael Quirmbach, Chief Executive Officer & President of CordenPharma, said: “We welcome the three sites and their employees as new members of the CordenPharma Group and look forward to working with Vifor in the future to supply Vifor Pharma’s finished medicinal products, including to theirs existing customers. The acquired pharmaceutical sites have well-trained employees with a very good cultural fit, state-of-the-art infrastructure and a solid track record of compliance. This excellent opportunity fits well with our strategy to expand our CDMO capabilities.”
The acquisition of Vifor Pharma’s manufacturing facilities will expand CordenPharma’s capabilities and capacity in the manufacture of non-sterile pharmaceutical dosage forms, particularly solid oral dosage forms such as tablets and capsules. With these three new facilities, CordenPharma’s global network now consists of 12 sites (11 GMP sites and 1 R&D lab) supported by more than 2,600 employees with expected sales of over €800m in 2022.
About Corden Pharma
CordenPharma, the global pharmaceutical services and manufacturing platform of International Chemical Investors Group (ICIG), is a full-service contract development and manufacturing (CDMO) partner for active ingredients, excipients, pharmaceuticals and related packaging services. Through a growing network of cGMP facilities across Europe and the US, organized into five technology platforms – Peptides, Lipids & Carbohydrates, Injectables, High Potency Drugs & Oncology and Small Molecules – CordenPharma’s experts implement complex processes and projects at every stage of development into high-quality products.
Original content from: CordenPharma, transmitted by news aktuell